BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amivantamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amivantamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05117931-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05117931)
DESCRIPTION:Amivantamab\, phase 2.\nStudy: A Study of Amivantamab in People
  With Esophagogastric Cancer\nEstimated primary completion: November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05117931
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06816992-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Amivantamab: Phase 1 readout est. (NCT06816992)
DESCRIPTION:Amivantamab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: ORI
 C-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR E
 xon20 Insertion Mutant NSCLC\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06816992
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06507306-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Amivantamab: Phase 1 readout est. (NCT06507306)
DESCRIPTION:Amivantamab\, phase 1.\nStudy: A Study to Investigate the Safet
 y and Efficacy of KQB198 as Monotherapy and in Combination in Participants
  With Advanced Solid Malignancies\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 7306
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02609776-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Amivantamab: Phase 1 readout est. (NCT02609776)
DESCRIPTION:Amivantamab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Amivantamab\, a Human Bispecific EGFR and cMet Antibody\, in Partici
 pants With Advanced Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02609776
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Combination Therapy With Amivantamab and Cetrelimab in Participa
 nts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05908734
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077463-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Amivantamab: Phase 1 readout est. (NCT04077463)
DESCRIPTION:Amivantamab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Lazertinib as Monotherapy or in Combination With Amivantamab in Pa
 rticipants With Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: 12 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04077463
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379595-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05379595)
DESCRIPTION:Amivantamab\, phase 1/2\, Colorectal Cancer.\nStudy: A Study of
  Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy 
 in Participants With Advanced or Metastatic Colorectal Cancer\nEstimated p
 rimary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05379595
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488314-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Capmatinib Combination Therapy in Unresectable M
 etastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0548
 8314
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855849-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06855849)
DESCRIPTION:Amivantamab\, phase 2\, Colorectal Cancer.\nStudy: An Open-labe
 l\, Single-arm\, Multicenter Phase II Study to Evaluate the Efficacy of Am
 ivantamab in Combination With FOLFIRI as a Second-line Treatment in Patien
 ts With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior
  Anti-EGFR Based Treatment.\nEstimated primary completion: May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855849
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Amivantamab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operativ
 e Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer
  (UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767075-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT03767075)
DESCRIPTION:Amivantamab\, phase 2.\nStudy: A Modular Multi-Basket Trial to 
 Improve Personalized Medicine in Cancer Patients (Basket of Baskets)\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03767075
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enh
 anced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growt
 h Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treate
 d First-line With Amivantamab Plus Lazertinib\nEstimated primary completio
 n: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiva
 ntamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06120140
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632236-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Amivantamab: Phase 1 readout est. (NCT06632236)
DESCRIPTION:Amivantamab\, phase 1.\nStudy: 5G-EMERALD: Amivantamab in Malig
 nant Brain Tumours\nEstimated primary completion: 1 July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06632236
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784791-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06784791)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pre
 operative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment 
 in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic
  EGFR Mutations (NEOpredict-EGFR)\nEstimated primary completion: 31 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06784791
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Participants With Advanced or Metastatic Solid Tumo
 rs Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cel
 l Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392658-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07392658)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC P
 atients With EGFR exon20 Insertion Mutations.\nEstimated primary completio
 n: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07392658
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05801029)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Investigate Safety and Efficacy of Osimertinib and Amivantamab in 
 Participants With Non-small Cell Lung Cancer With Common Epidermal Growth 
 Factor Receptor Mutations\nEstimated primary completion: 1 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05801029
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107230-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271118
DTEND;VALUE=DATE:20271119
SUMMARY:Amivantamab: Phase 1 readout est. (NCT07107230)
DESCRIPTION:Amivantamab\, phase 1.\nStudy: A Study of JNJ-95437446 in Parti
 cipants With Advanced-Stage Solid Tumors\nEstimated primary completion: 18
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiva
 ntamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07107230
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06750094-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06750094)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Partici
 pants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previou
 sly Received Chemotherapy\nEstimated primary completion: 15 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06750094
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083857-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06083857)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Ce
 ll Lung Cancer\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06083857
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in 
 Participants With Resectable EGFR-Mutated NSCLC\nEstimated primary complet
 ion: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/am
 ivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07586202
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744529-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07744529)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 mivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated L
 ung Adenocarcinoma\nEstimated primary completion: 28 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07744529
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06116682-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06116682)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tar
 geted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased
  Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)\nEstimated 
 primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06116682
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07798921-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Amivantamab: Phase 1 readout est. (NCT07798921)
DESCRIPTION:Amivantamab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: JIN
 -A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI
  Failure\nEstimated primary completion: 1 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07798921
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062354-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07062354)
DESCRIPTION:Amivantamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Combined Amivantamab\, Carboplatin and Paclitaxel in Unresectable 
 Locally Recurrent or Metastatic Head and Neck Cancer\nEstimated primary co
 mpletion: October 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07062354
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Olomorasib Combination Therapy in Participants W
 ith Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07227025
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06662786-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Amivantamab: Phase 3 readout est. (NCT06662786)
DESCRIPTION:Amivantamab\, phase 3\, Colorectal Cancer.\nStudy: A Study of A
 mivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIR
 I as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-typ
 e Unresectable or Metastatic Left-sided Colorectal Cancer\nEstimated prima
 ry completion: 15 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06662786
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808359-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07808359)
DESCRIPTION:Amivantamab\, phase 2.\nStudy: Amivantamab in Patients With Met
 astatic/Recurrent Penile Squamous Cell Carcinoma\nEstimated primary comple
 tion: February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07808359
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07042295-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07042295)
DESCRIPTION:Amivantamab\, phase 2.\nStudy: Treatment With Amivantamab and H
 yaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weaken
 ed Immune System\nEstimated primary completion: 28 February 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07042295
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Com
 bination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fa
 ctor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Amivantamab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Amivantamab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (SOC
 ) Compared With SOC Alone in Participants With Recurrent/Metastatic Head a
 nd Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469488-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Amivantamab: Phase 4 readout est. (NCT07469488)
DESCRIPTION:Amivantamab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Manage
 ment (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving
  Amivantamab-Based Regimens\nEstimated primary completion: 31 August 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07469488
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07507188)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Col
 laborative Clinical-translational Cohort of Amivantamab Plus Lazertinib an
 d Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Locally Adv
 anced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)\nE
 stimated primary completion: 31 January 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amivantamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-2020@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Amivantamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment A
 gents in Participants With Head and Neck Cancer\nEstimated primary complet
 ion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06385080
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
